Generating AI analysis...
Revenue
$48.19B
-0.22% YoY
EPS (Basic)
$3.47
++178.68% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $48.19B | $48.3B | -0.22% |
Cost of Revenue | $13.94B | $13.97B | -0.23% |
Net Income | $7.05B | $-8.95B | +178.83% |
EPS (Basic) | $3.47 | $-4.41 | +178.68% |
EPS (Diluted) | $3.46 | $-4.41 | +178.46% |
R&D Expense | $9.95B | $11.16B | -10.83% |
SG&A Expense | $7.27B | $8.41B | -13.63% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $90.04B | $92.6B | -2.77% |
Current Assets | $29.39B | $29.78B | -1.31% |
Total Liabilities | $71.53B | $76.22B | -6.14% |
Current Liabilities | $23.42B | $23.77B | -1.50% |
Stockholders' Equity | $18.47B | $16.34B | +13.09% |
Cash & Equivalents | $10.21B | $10.35B | -1.32% |
Long-Term Debt | $44.83B | $49.43B | -9.31% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $14.16B | $15.19B | -6.81% |
Investing Cash Flow | $-4.13B | $-21.35B | +80.65% |
Financing Cash Flow | $-10.35B | $5.13B | -301.83% |
Dividends Paid | $5.04B | $4.86B | +3.74% |
Share Buybacks | $0 | $0 | — |
D&A | $4.01B | $9.6B | -58.22% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 14.6% | — | — |
ROE | 38.2% | — | — |
ROA | 7.8% | — | — |
Current Ratio | $1.255 | — | — |
Debt to Equity | $3.872 | — | — |
Other companies in Pharmaceuticals